Literature DB >> 14402775

The role of the cycloserine (seromycin) blood level in the treatment of pulmonary tuberculosis and the prevention and control of cycloserine (seromycin) toxicity.

C X HOLMES, G E MARTIN, K I FETTERHOFF.   

Abstract

Entities:  

Keywords:  CYCLOSERINE/therapy; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1959        PMID： 14402775     DOI： 10.1378/chest.36.6.591

Source DB:  PubMed          Journal:  Dis Chest        ISSN： 0096-0217


× No keyword cloud information.
  4 in total

Review 1.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 2.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

3.  Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Authors:  Wael A Alghamdi; Abdullah Alsultan; Mohammad H Al-Shaer; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; Stephan Schmidt; Scott K Heysell; Russell R Kempker; J Peter Cegielski; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China.

Authors:  Yang Li; Fei Wang; Limin Wu; Min Zhu; Guiqing He; Xinchang Chen; Feng Sun; Qihui Liu; Xiaomeng Wang; Wenhong Zhang
Journal:  Infect Drug Resist       Date:  2019-03-29       Impact factor: 4.003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.